Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Paolo Tarantino, Ilaria Attili, Filippo de Marinis, Giuseppe Curigliano, Valeria Stati, Antonio Passaro
Publikováno v:
Lung Cancer. 154:151-160
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediate
Autor:
Lorenzo Spaggiari, Marina Chiara Garassino, Filippo de Marinis, Roberto Ferrara, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Gaia Piperno, Giuseppe Lo Russo, Giulia Corrao, Roberto Orecchia, Simone Giovanni Gugliandolo
Publikováno v:
Lung Cancer. 142:70-79
Presence of liver metastases correlates with worse survival and response to any treatments. This may be due to the microenvironment of liver which leads tumor to escape from Immune System. Stereotactic Body Radiation Therapy may help to sensitize Imm
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Oscar Alabiso, Vincenzo Adamo, Santi Barbera, Filippo de Marinis, R. Morena, Andrea Ardizzoni, Paolo Maione, Cesare Gridelli, Paola Venturino, Sandro Barni, Vito Lorusso, Vittorio Gebbia, E. Piazza, Calogero Buscarino, Nicoletta Zilembo, Alberto Caprioli, Maurizio Marangolo, Lucio Crinò, Riccardo Pela, Gianfranco Filippelli
Publikováno v:
Lung Cancer. 74:462-468
Lung cancer is the most common cancer in the world today, in terms of both incidence and mortality. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and the majority of people diagnosed with NSCLC have locally advanced o
Autor:
Frances A. Shepherd, Filippo de Marinis, Cesare Gridelli, Andrea Ardizzoni, Massimo Di Maio, Rafael Rosell, Jean-Yves Douillard, Francesco Perrone, Christian Manegold, Robert Pirker, Luigi De Petris, Nasser H. Hanna
Publikováno v:
Lung Cancer. 68:319-331
Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). However, randomized trials have recently demonstrated the efficacy of several new drugs (pemetrexed, bevacizumab, cetuxima
Publikováno v:
Lung Cancer. 67:339-342
Purpose and methods To evaluate how the new strategic approaches impact on clinical practice for the treatment of advanced non-small cell lung cancer (NSCLC) in Italy, an Italian survey was launched through the Italian Association of Thoracic Oncolog
Publikováno v:
Lung Cancer. 66:141-149
Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthase and other folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma. Successively, it
Autor:
Luisa Meacci, Sergio Bracarda, Paolo Latini, Ernesto Maranzano, Filippo de Marinis, Verena De Angelis, Panizza Bm, Fabrizio Piro, S. Darwish, Maurizio Tonato, Lucio Crinò, Vincenzo Minotti
Publikováno v:
Lung Cancer. 37:79-85
Background: Small cell lung cancer (SCLC) is a chemoresponsive tumor but overall survival remains poor even in limited disease (LD). With the aim of eradicating chemoresistant tumor cells and reducing toxicity, we investigated in this phase II trial
Publikováno v:
Lung Cancer. 82:511
Publikováno v:
Lung Cancer. 71:118